Manufacturing News of Note—Colorcon creates VC fund; FDA standardizing assessments; Upperton adds tableting


> Pharma supplier Colorcon has created a $50 million venture capital fund to invest in what a spokesman says would be new manufacturing technologies like track-and-trace systems and artificial intelligence solutions but not in companies that develop APIs or molecules. Release

> The FDA is creating a new system it expects will provide the information about the inherent risk and control approaches for product design, manufacturing and facilities to improve its quality assessments. Story

> Australian CDMO Cell Therapies says it is the first company in Australia to be granted a product class (T cells) GMP manufacturing license by regulators for commercial supply of the cells. Release

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

> U.K.-based clinical supply CDMO Upperton Pharma Solutions has invested in new tableting capabilities. Release

> French CMO Indicia Production has acquired Bio-Steril, also a French company, which specializes in the formulation and fill and finish of medical devices for medical and cosmetic uses. Release 

> GE Healthcare and the National Institute of Bioprocessing Research and Training in Dublin are working together to create training programs in biopharmaceutical and cell therapy development and manufacturing. Release

> CDMO Pharmaceutics International will manufacturer Sagent Pharmaceuticals' recently approved fulvestrant injection.  Release



Suggested Articles

Nearly four decades after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.

Amidst a gung-ho shift to oncology, Daiichi is also fleshing out its gene therapy capacity with a $200 million licensing deal with Ultragenyx.